BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$177.34
-6.44 (-3.50%)
▼
5d:
-7.18%
30d:
-6.63%
90d:
+0.77%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
BIIB is down 3.6% this week, but smart money is accumulating calls. Top strike: $180 2026-04-17 with 394 OI. Call ratio: 69% View Scanner →
Strength: 3.7/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BIIB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BIIB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$225.77
Based on 3.7% avg growth
INTRINSIC VALUE TODAY
$140.19
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $177.34, which is considered oversold relative to its 30-day fair value range of $182.27 to $190.78. The stock's valuation (Forward PE: 11.3) is in line with its historical norms (11.6). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 19.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $171.37, while resistance sits at $192.28. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: BIIB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $205.90 (+12.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $171.37, while resistance sits at $192.28. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: BIIB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $205.90 (+12.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$182.27 -
$190.78
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading below Wall St target ($205.90)
- CAUTION: 5-day price weakness (-7.2%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$182.27 -
$190.78
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$171.37
Resistance Level
$192.28
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.32
Wall Street Target
$205.90
(+12.0%)
Revenue Growth (YoY)
-7.1%
Earnings Growth (YoY)
19.2%
Profit Margin
13.1%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
11.3 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$182.31
(-1%)
2-Year Target
$180.85
(-2%)
3-Year Target
$179.40
(-2%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$183.79
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 3.4%)
$401.04
(+118%)
Base:
(SPY PE: 11.3, Growth: 3.4%)
$203.18
(+11%)
Bear:
(PE: 9.6, Growth: 3.4%)
$172.71
(-6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 20.67 | Current EPS (TTM): $8.78
Bull Case
$368.98
(+101%)
Analyst growth 84.9%, PE expands to 22.7
Base Case
$335.44
(+83%)
Market implied 84.9%, PE stable at 20.7
Bear Case
$123.39
(-33%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.3 to 11.6
Stabilization Target:
$188.27
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: April 02, 2026 4:49 PM ET
Data refreshes hourly during market hours. Next update: 5:49 PM
Data refreshes hourly during market hours. Next update: 5:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 57 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 60 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 54 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$128 | 62 BUY |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
